Barclays raised the firm’s price target on Abbott (ABT) to $144 from $142 and keeps an Overweight rating on the shares. The firm updated the company’s model to reflect the Exact Sciences acquisition.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABT:
- Abbott price target lowered to $134 from $138 at Evercore ISI
- Abbott price target lowered to $131 from $140 at BTIG
- Abbott integrates Precision Oncology portfolio into Flatiron’s OncoEMR
- This Leading Pharma Company Has Grown Its Dividend 70% Since 2020
- Wall Street’s 3 Safe Bets as Fed’s Powell Downplays Stagflation, But Sees ‘Some Tension Between the Goals’